Impact of withdrawal of the analgesic co-proxamol on nonfatal self-poisoning in the UK

Crisis

Volumn 32, Issue 2, 2011, Pages 81-87

  Hawton, Keith ^a   Bergen, Helen ^a   Waters, Keith ^b   Murphy, Elizabeth ^c   Cooper, Jayne ^c   Kapur, Navneet ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DERBYSHIRE HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Co proxamol; Self poisoning; Time trends

Indexed keywords

ACETAMINOPHEN, DEXTROPROPOXYPHENE, DRUG COMBINATION; ANALGESIC AGENT; DEXTROPROPOXYPHENE; PARACETAMOL;

ARTICLE; AUTOMUTILATION; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG RECALL; DRUG SUBSTITUTION; EMERGENCY HEALTH SERVICE; GENERAL HOSPITAL; HUMAN; INTOXICATION; STATISTICS; SUICIDE ATTEMPT; UNITED KINGDOM;

ACETAMINOPHEN; ANALGESICS; CROSS-SECTIONAL STUDIES; DEXTROPROPOXYPHENE; DRUG COMBINATIONS; DRUG SUBSTITUTION; EMERGENCY SERVICE, HOSPITAL; ENGLAND; HOSPITALS, GENERAL; HUMANS; OVERDOSE; SAFETY-BASED DRUG WITHDRAWALS; SELF-INJURIOUS BEHAVIOR; SUICIDE, ATTEMPTED;

EID: 79959497765     PISSN: 02275910     EISSN: None     Source Type: Journal    
DOI: 10.1027/0227-5910/a000063     Document Type: Article

References (21)

1. Bateman, D. N., & Afshari, R. (2003). Licence needs to be changed. British Medical Journal, 327, 287.
2. Committee on Safety of Medicines. (2006). Withdrawal of coproxamol (distalgesic, cosalgesic, dolgesic). Current Problems in Pharmacovigilance, 31, 1.
3. Drug and Therapeutics Bulletin. (1983). Distalgesic and its equivalents: Time for action. Drug and Therapeutics Bulletin, 21, 17-19.
4. European Medicines Agency. (2009). European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines. European Medicines Agency [online]. Retrieved from http://www.emea.europa.eu/pdfs/human/press/pr/40106209en.pdf.
5. Hawton, K., Bergen, H., Casey, D., Simkin, S., Palmer, B., Cooper, J., Owens, D. (2007). Self-harm in England: A tale of three cities. Multicentre study of self-harm. Social Psychiatry and Psychiatric Epidemiology, 42, 513-521.
6. Hawton, K., Bergen, H., Simkin, S., Brock, A., Griffiths, C., Romeri, E., Gunnell, D. (2009). Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England andWales: Time series analysis. BMJ, 338, b2270.
7. Hawton, K., Harriss, L., Hall, S., Simkin, S., Bale, E., & Bond, A. (2003). Deliberate self-harm in Oxford, 1990-2000: a time of change in patient haracteristics. Psychological Medicine, 33, 987-996.
8. Hawton, K., Simkin, S., & Deeks, J. J. (2003). Co-proxamol and suicide: A study of national mortality statistics and local nonfatal self-poisonings. BMJ, 26, 1006-1008.
9. Hawton, K., Simkin, S., Gunnell, D., Sutton, L., Bennewith, O., Turnbull, P., & Kapur, N. (2005). A multicentre study of coproxamol poisoning suicides based on coroners' records in England. British Journal of Clinical Pharmacology, 59, 207-212.
10. Medicines and Healthcare products Regulatory Agency (MHRA). (2005). Withdrawal of co-proxamol products and interim updated prescribing information CEM/CMO/2005/2. Medicines and Healthcare products Regulatory Agency (MHRA) [Online]. Retrieved from http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con019461.pdf.
11. Office for National Statistics. (2007). Deaths related to drug poisoning: England and Wales, 1993-2005. Health Statistics Quarterly, 33, 82-88.
12. Ramsay, C. R., Matowe, L., Grilli, R., Grimshaw, J. M., & Thomas, R. E. (2003). Interrupted time series designs in health technology assessment: Lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care, 19, 613-623.
13. Sandilands, E. A., & Bateman, D. N. (2008). Co-proxamol withdrawal has reduced suicide from drugs in Scotland. British Journal of Clinical harmacology, 66, 290-293.
14. Simkin, S., Hawton, K., Sutton, L., Gunnell, D., Bennewith, O., & Kapur, N. (2005). Co-proxamol and suicide: A review to inform initiatives to prevent the continuing toll of overdose deaths. Quarterly Journal of Medicine, 98, 159-170.
15. Stata Corporation. (2007). Stata statistical software: Release 10. College Station, TX: Author.
16. The Information Centre for health and social care, P. S. U. (2006). Prescription cost analysis: England 2005. Leeds: Department of Health.
17. The Information Centre for health and social care, P. S. U. (2007). Prescription cost analysis: England 2006. Leeds: Department of Health.
18. US Food and Drug Administration. (2009a). FDA [On-line]. Retrieved from http://www.fda.gov/default.htm.
19. US Food and Drug Administration. (2009b). FDA takes actions on Darvon, other pain medications containing propoxyphene. FDA [Online]. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170769.htm.
20. Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002). Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics, 27, 299-309.
21. Zhang, F., Wagner, A., Soumerai, S.B., & Ross-Degnan, D. (2002). Estimating confidence intervals around relative changes in outcomes in segmented regression analyses of time series data. 15th Annual NESUG (NorthEast SAS Users Group Inc) Conference [On-line]. Retrieved from http://www.nesug.info/Proceedings/nesug02/st/st005.pdf.